Abstract
Abstract
Background
Desmoid tumours (DTs) or deep fibromatosis are benign soft-tissue tumours, sometimes locally aggressive, requiring intervention on some cases. Surgery has been the gold standard, but new less invasive techniques such as percutaneous cryoablation have proved their effectiveness, reducing health resources and complications. The study aimed to compare the total cost of percutaneous cryoablation and conventional surgery for patients with extra-abdominal and/or abdominal wall DTs, candidates for local ablative treatment in Spain.
Methods
A cost-analysis model was developed. An expert panel provided data about resource consumption for the percutaneous cryoablation technique and validated the epidemiology used for target population estimation. Unitary resources cost (€ 2022) derived from local cost databases. A retrospective analysis of 54 surgical cases in 3 Spanish hospitals was performed to estimate the cost of conventional surgery based on the cost of the Diagnosis-Related group (DRG) codes identified on this patient sample, weighted by each DRG proportion. The total cost for each alternative included intervention cost and complications cost, considering debridement required in 4.5% of cases with percutaneous cryoablation and minor surgery for surgical site infection in 18.0% for conventional surgery.
Results
The total cost for percutaneous cryoablation (€ 5774.78/patient-year) was lower than the total cost for conventional surgery (€ 6780.98/patient-year), yielding cost savings up to € 80,002 in 1 year for the entire cohort of 80 patients with DTs eligible for intervention estimated in Spain. One-way sensitivity analyses confirmed the results’ robustness.
Conclusion
Percutaneous cryoablation versus conventional surgery would yield cost savings for the management of DT patients in Spain.
Critical relevance statement
This manuscript provides insight into the economic impact derived from the savings related to the use of percutaneous cryoablation for desmoid-type tumours from the perspective of the Spanish National Healthcare System, providing useful information for the health decision-making process.
Key points
• Desmoid tumours are locally aggressive and may require local therapy.
• Percutaneous cryoablation procedure is less invasive than the conventional surgery.
• Cost comparison shows savings associated to percutaneous cryoablation use.
Graphical Abstract
Funder
Boston Scientific Corporation
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging
Reference43 articles.
1. Kurtz JE, Buy X, Deschamps F, et al. (2021) CRYODESMO-O1: A prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment. Eur J Cancer 143:78–87. https://doi.org/10.1016/j.ejca.2020.10.035
2. Saltiel S, Bize PE, Goetti P, et al. (2020) Cryoablation of Extra-Abdominal Desmoid Tumors: A Single-Center Experience with Literature Review. Diagnostics (Basel) 10(8):556. https://doi.org/10.3390/diagnostics10080556
3. Fritchie KJ, Cargo AM, van de Rijn M (2020) Desmoid Fibromatosis: WHO Classification of Tumours 5th Edition. Soft Tissue and Bone Tumours. Editorial Board. International Agency for Research on Cancer., Lyon, pp 93–95
4. Auloge P, Garnon J, Robinson JM, et al. (2021) Percutaneous cryoablation for advanced and refractory extra-abdominal desmoid tumors. Int J Clin Oncol 26(6):1147–1158. https://doi.org/10.1007/s10147-021-01887-y
5. Mankin HJ, Hornicek FJ, Springfield DS (2010) Extra-abdominal desmoid tumors: a report of 234 cases. J Surg Oncol 102(5):380–384. https://doi.org/10.1002/jso.21433